Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2012
08/02/2012US20120195916 Method of treating cancer by inhibiting trim59 expression or activity
08/02/2012US20120195914 Aldosterone induced elastin production
08/02/2012US20120195911 Method of treatment of cancer patients
08/02/2012US20120195906 Method for diagnosing and treating emphysema
08/02/2012US20120195901 Compositions and Methods for Binding Lysophosphatidic Acid
08/02/2012US20120195897 Human domain antibodies against components of the human insulin-like growth factor (igf) system
08/02/2012US20120195890 Oligonucleotides inhibiting cellular migration
08/02/2012US20120195887 Inhibitor Compounds and Cancer Treatment Methods
08/02/2012US20120195881 Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions and their use
08/02/2012US20120195873 Methods of attenuating the loss of functional status
08/02/2012US20120195871 Stable aqueous suspension
08/02/2012US20120195870 Preparations with wood extracts of locust trees
08/02/2012US20120195861 Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
08/02/2012US20120195857 Hepatitis C Virus Inhibitors
08/02/2012US20120195856 Method of treating patients with cardiovascular illness
08/02/2012US20120195850 Use of polymer d-lactic acid (pdla) or equivalents thereof to inhibit growth of cancer cells and diagnose cancers
08/02/2012US20120195847 Polymer conjugates of biphalin peptides
08/02/2012US20120195846 Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
08/02/2012US20120195832 Process for producing an injectable medicament preparation
08/02/2012US20120195827 Myocardial perfusion imaging methods and compositions
08/02/2012US20120192861 Aerosol pirfenidone and pyridone analog compounds and uses thereof
08/02/2012DE102011009961A1 7-Azaindolderivate 7-azaindole derivatives
08/02/2012DE102011003315A1 New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful for treating and/or preventing e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease, and fibrotic disorder
08/02/2012CA2826034A1 Stilbene analogs and methods of treating cancer
08/02/2012CA2826019A1 Remedy for migraine headache
08/02/2012CA2825907A1 Small molecule rnase inhibitors and methods of use
08/02/2012CA2825906A1 Compounds for the reduction of .beta.-amyloid production
08/02/2012CA2825905A1 Small molecule rnase inhibitors and methods of use
08/02/2012CA2825889A1 Topical antifungal agent
08/02/2012CA2825878A1 Arylalkyl esters of 4-amino-6-(substituted phenyl)picolinates and 6-amino-2-(substituted phenyl)-4-pyrimidinecarboxylates and their use as herbicides
08/02/2012CA2825877A1 Oral dosage forms for modified release comprising tasocitinib
08/02/2012CA2825858A1 Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compound and application
08/02/2012CA2825825A1 Inhibitors of mtor kinase as anti-viral agents
08/02/2012CA2825816A1 Analgesic compounds, methods, and formulations
08/02/2012CA2825810A1 Use of potassium channel blockers to treat cerebral palsy
08/02/2012CA2825790A1 Combinations
08/02/2012CA2825779A1 Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
08/02/2012CA2825746A1 Pyrazolopyridine derivative or pharmacologically acceptable salt thereof
08/02/2012CA2825716A1 Use of (s) -esmolol for controlling venous irritation associated with the treatment of a cardiac disorder
08/02/2012CA2825684A1 Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
08/02/2012CA2825458A1 Pyrazole compounds as crth2 antagonists
08/02/2012CA2825417A1 Liposome and personal care composition comprising thereof
08/02/2012CA2825408A1 Tetrazole compounds and methods of making and using same
08/02/2012CA2825396A1 Androgen composition for treating an opthalmic condition
08/02/2012CA2825389A1 Process for the preparation of 4-amino-3-chloro-5-fluoro-6-(substituted)picolinates
08/02/2012CA2825311A1 Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension
08/02/2012CA2825309A1 Methods for treating obstructive sleep apnea
08/02/2012CA2825306A1 Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
08/02/2012CA2825298A1 Methods and compositions for preparing noribogaine from voacangine
08/02/2012CA2825256A1 Drug delivery systems
08/02/2012CA2825252A1 Compositions and methods for cell transplantation
08/02/2012CA2825172A1 Indole derivative and pharmacologically acceptable salt of same
08/02/2012CA2825142A1 Use of nicotinic acetylcholine receptor alpha 7 activators
08/02/2012CA2825134A1 Indole derivative, and pharmacologically acceptable salt thereof
08/02/2012CA2825098A1 Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
08/02/2012CA2824982A1 Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
08/02/2012CA2824941A1 Testosterone formulations
08/02/2012CA2824766A1 Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
08/02/2012CA2824679A1 Pharmaceutical composition comprising pyridone derivatives
08/02/2012CA2824536A1 Protease activated receptor 2 (par2) antagonists
08/02/2012CA2824467A1 Pharmaceutical composition comprising pyridone derivatives
08/02/2012CA2824078A1 Histone deacetylase inhibitors and compositions and methods of use thereof
08/02/2012CA2823824A1 Derivatives of azaindazole or diazaindazole type as medicament
08/02/2012CA2823804A1 Novel tetrahydroquinoline derivatives
08/02/2012CA2823781A1 New aryl-benzocycloalkyl amide derivatives
08/02/2012CA2823774A1 Inhibitors of branched-chain-aminotransferase-1 (bcat1) for the treatment of brain tumors
08/02/2012CA2823218A1 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
08/02/2012CA2822120A1 Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
08/01/2012EP2481802A2 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
08/01/2012EP2481801A1 Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
08/01/2012EP2481747A1 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
08/01/2012EP2481741A1 Compositions comprising substantially pure fluorescein
08/01/2012EP2481739A1 Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof
08/01/2012EP2481738A1 Maleic acid salt and crystal thereof
08/01/2012EP2481736A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
08/01/2012EP2481735A1 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
08/01/2012EP2481732A1 Condensed ring compound and use thereof
08/01/2012EP2481729A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases
08/01/2012EP2481727A1 TRPM8 receptor antagonists
08/01/2012EP2481726A2 Crystal forms of saxagliptin and processes for preparing same
08/01/2012EP2481725A1 Substituted amide compound
08/01/2012EP2481723A2 Substituted tetracycline compounds
08/01/2012EP2481417A1 Lactase preparation
08/01/2012EP2481414A1 A process for the preparation of cross-linked polyallylamines or pharmaceutically acceptable salts thereof
08/01/2012EP2481413A1 Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals
08/01/2012EP2481412A1 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
08/01/2012EP2481411A1 Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
08/01/2012EP2481410A1 Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
08/01/2012EP2481409A2 Nanoparticle comprising rapamycin and albumin as anticancer agent
08/01/2012EP2481408A2 New use of glutaminyl cyclase inhibitors
08/01/2012EP2481407A1 Compounds for use in treating cognitive disorders
08/01/2012EP2481406A1 Use of piperphentonamine or salts thereof in manufacture of medicaments for preventing / treating brain diseases
08/01/2012EP2481405A1 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
08/01/2012EP2481404A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
08/01/2012EP2481403A1 Pharmaceutical combination of otilonium and trimebutine
08/01/2012EP2481402A2 Nanoparticle comprising rapamycin and albumin as anticancer agent
08/01/2012EP2481400A1 Oral controlled release compositions comprising vitamin D compound and waxy carrier
08/01/2012EP2481398A1 Slow-release cilostazol tablet having an improved elution rate and minimal side effects
08/01/2012EP2481397A1 Pharmaceutical compositions comprising tasocitinib
08/01/2012EP2481396A2 Oxaliplatin nanoparticles and method for preparing same
1 ... 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 ... 7860